CAS 2088281-24-5 CAQK Peptide

Send Inquiry
CAS 2088281-24-5 CAQK Peptide
Details
•CAS: 2088281-24-5
•Synonyms: CAQK peptide; Cys-Ala-Gln-Lys; Brain injury-homing peptide
•Core structure: Linear tetrapeptide with sequence Cys-Ala-Gln-Lys (CAQK), composed of cysteine, alanine,
glutamine, and lysine. A brain injury-homing peptide identified through phage display technology, specifically binds chondroitin sulfate proteoglycan (CSPG) complexes upregulated in the extracellular matrix of acutely injured brain tissue, does not bind healthy brain tissue, used for targeted drug delivery to CNS injuries and neuroprotection research.
•We also provide specifications from crude to 99% purity. Please contact us for details!
Related documents
•COA/MS/HPLC Report
Category
Drug Delivery Peptides
Share to
Description

Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of cas 2088281-24-5 caqk peptide in China, also supports custom service. Welcome to wholesale bulk high quality cas 2088281-24-5 caqk peptide from our factory. Contact us for more details.

 

Product Name CAQK peptide
Description CAQK peptide (CAQK peptide), CAS 2088281-24-5, with sequence Cys-Ala-Gln-Lys (CAQK), is a brain injury-homing peptide identified through phage display technology, discovered by the team of Erkki Ruoslahti at the Sanford Burnham Prebys Medical Discovery Institute. This tetrapeptide specifically recognizes and binds chondroitin sulfate proteoglycan (CSPG) glycoprotein complexes upregulated in the extracellular matrix (ECM) of acutely injured brain and spinal cord tissue, without interacting with healthy brain tissue or other normal tissues. Its targeting homing ability is mediated by injury-induced molecular signatures, including blood-brain barrier (BBB) disruption and ECM component exposure. In multiple murine brain injury models, fluorescently labeled CAQK (FAM-CAQK, Cy5-CAQK) rapidly and selectively accumulates at demyelinating injury sites and traumatic brain injury regions, and this binding is dose-dependent and can be competitively inhibited by excess unlabeled peptide, indicating high specificity. CAQK peptide has a small molecular weight (448 Da), strong polarity, and a LogP of approximately 0.1. After intravenous injection, it rapidly distributes to injured brain tissue, can cross the blood-brain barrier in injury models with compromised BBB, has a rodent plasma half-life of approximately 1–2 hours, and is primarily excreted through the kidneys. This peptide has been used to target nanoparticles, silencing oligonucleotides (siRNA), and other therapeutic payloads to CNS injury sites, and has demonstrated direct neuroprotective effects in traumatic brain injury models (reducing lesion volume, attenuating neuroinflammation, reducing apoptosis, and improving functional recovery). The N-terminal cysteine residue provides a thiol conjugation site for facile attachment to drugs, probes, or nanocarriers. CAQK peptide has shown no apparent toxicity in preclinical studies and is currently being developed for potential clinical applications by Aivocode.
Peptide Purity (HPLC, %) ≥98%
Molecular formula C₁₇H₃₂N₆O₆S
Molecular weight (Da) 448.54

 

Product Basic Information Table

 

Product Standard English Name Product Abbreviation / Alias Function Tags (comma-separated) Core Structure Molecular Formula Exact Mass (Da) Average MW (Da) Salt Form Length (aa)
CAQK peptide CAQK glioma-targeting peptide; blood-brain barrier penetrating peptide Brain tumor targeting peptide, blood-brain barrier penetration, glioma-targeted delivery, drug/gene vector Linear tetrapeptide Cys-Ala-Gln-Lys, cationic peptide; specifically binds chondroitin sulfate proteoglycans overexpressed on glioma cells, mediating blood-brain barrier penetration and tumor accumulation C₁₇H₃₁N₅O₅S 405.2 ~405.5 Acetate 4

Physicochemical Solubility & Storage Parameters

 

Product Code Appearance Long-term Storage Short-term Storage Solution Stability Solid Powder Stability
PEP-CAQ001 White powder Store at -20°C, sealed, dry and protected from light. Aliquot for storage. Stable for 1 month at 2–8°C in sealed dry condition; stable for shipping at ambient temperature. Stable for 7 days at 4°C. Acetate salt is freely soluble in water, dilute acetic acid and PBS. Good stability of cationic peptide under acidic to neutral conditions; charge neutralization and targeting activity loss under strong alkaline conditions. Stable for 2 years at -20°C, dry and protected from light.

Functional Description

 

Product Code Frontend Short Summary (for search list display) Detailed Biological Function Description Applicable Research Areas (comma-separated) Targets / Pathways
PEP-CAQ001 CAQK peptide targets glioma proteoglycans for blood-brain barrier drug delivery CAQK peptide is a specific targeting peptide screened for glioma. It specifically binds chondroitin sulfate proteoglycans overexpressed on glioma cells and tumor neovasculature, mediating penetration of peptides, nanoparticles and nucleic acid drugs across the blood-brain barrier and accumulation in tumor tissue. It significantly improves brain tumor delivery efficiency of chemotherapeutics and gene drugs while reducing systemic side effects, serving as an important targeting vehicle for glioma targeted therapy and diagnosis research. Brain tumor targeted therapy, blood-brain barrier delivery, glioma research, targeted drug development, molecular imaging Chondroitin sulfate proteoglycan; blood-brain barrier penetration pathway; receptor-mediated endocytosis

 

 

 

 

 

 

 

 

 

 

 

 

Hot Tags: cas 2088281-24-5 caqk peptide, China cas 2088281-24-5 caqk peptide manufacturers, suppliers, factory, 395069-92-8, CAS 203716 10 3, CAS 395069 92 8, CAS 997 20 6, MPG Peptide, therapeutic and pharmaceutical peptides

Send Inquiry